Streetbeat News

Analyst Ratings

NTLA

Over the past 3 months, 10 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock, with 2 bullish, 7 somewhat bullish, and 1 indifferent. The company has an average 12-month price target of $74.4, down 6.84% from the previous average of $79.86.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 4:04 pm

ORCL

Wolfe Research analyst Alex Zukin maintains an Outperform rating on Oracle (NYSE:ORCL) and raises the price target from $130 to $140.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 4:04 pm

OCUL

Ocular Therapeutix (NASDAQ:OCUL) has received 2 bullish and 3 somewhat bullish ratings from analysts in the last quarter. The average 12-month price target for the stock is $12.8, up 19.96% from the previous average of $10.67.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 4:03 pm

CLVT

Clarivate (NYSE:CLVT) has received mixed analyst ratings in the last quarter, with an average 12-month price target of $11.75, down 3.69% from the previous average of $12.20.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 4:03 pm

ORCL

Deutsche Bank analyst Brad Zelnick maintains a Buy rating on Oracle (NYSE:ORCL) and raises the price target from $120 to $135.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 4:02 pm

ADI

11 analysts have provided their ratings for Analog Devices (NASDAQ:ADI) in the last quarter, with 2 bullish, 7 somewhat bullish, and 2 indifferent. The average 12-month price target is $205.27, a 6.95% decrease from the previous average of $220.60.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 4:01 pm

LITE

In the last quarter, Lumentum Holdings (NASDAQ:LITE) received 3 bullish, 6 somewhat bullish, and 8 indifferent analyst ratings. The company's average 12-month price target is $54.47, down 18.6% from the previous average of $66.92.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 4:01 pm

ORCL

Barclays analyst Raimo Lenschow maintains an Equal-Weight rating on Oracle (NYSE:ORCL) and raises the price target from $113 to $126.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 4:01 pm

FWBI

In the last 3 months, 4 analysts have offered 12-month price targets for First Wave BioPharma (NASDAQ:FWBI), with an average price target of $12.0, a 25.0% decrease from the previous average price target of $16.00.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 4:00 pm

ORCL

Jefferies analyst Brent Thill maintains a Buy rating on Oracle (NYSE:ORCL) and raises the price target from $125 to $135.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 3:59 pm